ACORQ vs. SCNI, PKBO, GMDAQ, WINT, ELOX, EVLO, OSA, OSAP, BLPH, and TIVC
Should you be buying Acorda Therapeutics stock or one of its competitors? The main competitors of Acorda Therapeutics include Scinai Immunotherapeutics (SCNI), Peak Bio (PKBO), Gamida Cell (GMDAQ), Windtree Therapeutics (WINT), Eloxx Pharmaceuticals (ELOX), Evelo Biosciences (EVLO), ProSomnus (OSA), ProSomnus (OSAP), Bellerophon Therapeutics (BLPH), and Tivic Health Systems (TIVC). These companies are all part of the "medical" sector.
Acorda Therapeutics (NASDAQ:ACORQ) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
12.7% of Acorda Therapeutics shares are owned by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 2.6% of Acorda Therapeutics shares are owned by company insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Acorda Therapeutics has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500. Comparatively, Scinai Immunotherapeutics has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500.
In the previous week, Scinai Immunotherapeutics had 1 more articles in the media than Acorda Therapeutics. MarketBeat recorded 2 mentions for Scinai Immunotherapeutics and 1 mentions for Acorda Therapeutics. Scinai Immunotherapeutics' average media sentiment score of 0.16 beat Acorda Therapeutics' score of -0.95 indicating that Scinai Immunotherapeutics is being referred to more favorably in the news media.
Scinai Immunotherapeutics has a net margin of 0.00% compared to Acorda Therapeutics' net margin of -227.75%. Scinai Immunotherapeutics' return on equity of 0.00% beat Acorda Therapeutics' return on equity.
Scinai Immunotherapeutics has lower revenue, but higher earnings than Acorda Therapeutics. Scinai Immunotherapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.
Acorda Therapeutics and Scinai Immunotherapeutics both received 0 outperform votes by MarketBeat users.
Summary
Scinai Immunotherapeutics beats Acorda Therapeutics on 10 of the 12 factors compared between the two stocks.
Get Acorda Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACORQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACORQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ACORQ vs. The Competition
Acorda Therapeutics Competitors List
Related Companies and Tools
